<DOC>
	<DOC>NCT01431833</DOC>
	<brief_summary>Assess the single dose PK and safety of TR701 FA in subjects with Moderate or Severe hepatic impairment versus matched control subjects with normal hepatic function.</brief_summary>
	<brief_title>A PK and Safety Study in Subjects With Hepatic Impairment</brief_title>
	<detailed_description>This study will assess the single-dose pharmacokinetics (PK) and safety of TR-701 free acid (FA) in subjects with Moderate or Severe hepatic impairment compared with matched control subjects with normal hepatic function.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Moderate or severe hepatic impairment or matched control BMI between 18.0 and 40.0 kg/m2 Evidence of acute deterioration of hepatic function within 8 weeks ALT or AST ≥ 5 times upper limit of normal for moderates; ALT or AST ≥ 8 times upper limit of normal for severes Total bilirubin &gt; 5 mg/dl for moderates; no upper limit for severes Hemoglobin &lt; 10g/dl for moderates; Hemoglobin &lt; 9g/dl for severes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Matched control subjects</keyword>
</DOC>